{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282613","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.512325+00:00","generated_at":"2026-06-21T23:45:05.018436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd Q3 net loss $45.1M; cash $419M; NVD200 on track for Q1 2023 trial","bullets":["Net loss of $45.1M ($0.42 per share) vs $60.4M ($0.98) in Q3 2021; R&D expenses fell to $34.1M from $49.4M.","Cash, cash equivalents and marketable securities of $419M as of Sept 30, 2022; expected runway into Q2 2024.","NVD200 combination antibody candidate progressing toward clinical trial start in Q1 2023; demonstrated potent in vitro neutralization against Omicron sublineages.","David Hering named permanent CEO in July; Fred Driscoll appointed interim CFO and Christine Lindenboom to board in October.","Entered Platform Transfer Agreement with Adimab and signed 9,600 sq ft lease in Newton, MA for expanded lab space."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282613","json":"https://secwatch.observer/filing/0001193125-22-282613.json","markdown":"https://secwatch.observer/filing/0001193125-22-282613.md","text":"https://secwatch.observer/filing/0001193125-22-282613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/0001193125-22-282613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/d407741d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:45:05.018436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c82871dec8d2646a02b2440e563994f96bd3de2c","claim":"Invivyd, Inc. reported the third quarter ended September 30, 2022 results: net income $45.1 million, EPS $0.42 per share.","evidence_excerpt":"Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/0001193125-22-282613-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$45.1 million"},{"label":"EPS","value":"$0.42 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}